Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 959

Sort by

Sort Order Select

Journal Articles

The journey of a thousand miles begins with 1 step

Luca Malcovati

Blood (2021) 138 (10): 824–826.

https://doi.org/10.1182/blood.2021012304

Published: 2021

Journal Articles

Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders

Blood (2019) 134 (23): 2082–2091.

https://doi.org/10.1182/blood.2018891192

Published: 2019

Includes: Supplemental data

Journal Articles

Association between Inflammatory Markers and Abnormal Neurological, Neurocognitive and Magnetic Resonance Imaging (MRI) Findings in Children with Sickle Cell Anemia in Uganda

Amelia Boehme, PhD MSPH, Adiba Ashrafi, MS, Richard Idro, MMED, PhD, Paul Bangirana, MS, PhD, Deogratias Munube, MD, Robert Opoka, MMED, Philip Kasirye, MMED, Margaret T. Lee, MD, Nancy S. Green, MD, Mady Hornig, MA, MD

Blood (2019) 134 (Supplement_1): 2300.

https://doi.org/10.1182/blood-2019-131560

Published: 2019

Journal Articles

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Julie Kanter, MD, Mary Dooley, MS, Logan P Sirline, MPH, Martina Mueller, PhD, Shannon Phillips, PhD RN, Alyssa M Schlenz, PhD, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS

Blood (2019) 134 (Supplement_1): 2270.

https://doi.org/10.1182/blood-2019-129951

Published: 2019

Journal Articles

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Chris Wynick, MD MSc, BSc, Joanne Britto, MD BSc, Daniel Sawler, MD BSc, Arabesque Parker, MD, Mohammad Karkhaneh, PhD, Dawn Goodyear, MD, Haowei Linda Sun, MDFRCPC

Blood (2019) 134 (Supplement_1): 2379.

https://doi.org/10.1182/blood-2019-126354

Published: 2019

Journal Articles

Faster Diagnosis of TTP Using New Technoscreen Adamts-13 Activity Assay

Annica Braf, Henrik von Horn, Niklas Bark, Eva-Marie Norberg, Asa Truedsson, Nikolaus B Binder, MD PhD, Jovan P Antovic, MD PhD

Blood (2019) 134 (Supplement_1): 2354.

https://doi.org/10.1182/blood-2019-128131

Published: 2019

Journal Articles

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

Blood (2019) 134 (Supplement_1): 5416.

https://doi.org/10.1182/blood-2019-129464

Published: 2019

Journal Articles

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Blood (2019) 134 (Supplement_1): 4237.

https://doi.org/10.1182/blood-2019-125974

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

Sabit Delic, PhD, Piers Blombery, MBBS, María José Calasanz, PhD, Devon S. Chabot-Richards, MD, Dolors Colomer, PhD, Matteo G Della Porta, MD, Paul A S Evans, PhD, Torsten Haferlach, MD, Joanne Mason, FRCPath, Jay L Patel, MD, William S. Stevenson, MBBS, PhD, Christian Thiede, MD, Maria Teresa Voso, MD, Jordan Clark

Blood (2019) 134 (Supplement_1): 5837.

https://doi.org/10.1182/blood-2019-128652

Published: 2019

Journal Articles

MRI Evaluation of Liver and Cardiac Iron Overload Impact on Hematopoietic Stem Cell Transplantation with β-Thalassemia Major

Libai Chen, MD, Yuelin He, MD, Jianyun Wen, Wenjing Yang, Xuan Liu, Yongsheng Ruan, MD, Xiaoqin Feng, Chunfu Li, MD, Xuedong Wu, MD PhD

Blood (2019) 134 (Supplement_1): 5738.

https://doi.org/10.1182/blood-2019-128903

Published: 2019

Journal Articles

Sensing and Sensibility: Programming Smarter Chimeric Antigen Receptor T Cells

Wendell Lim, PhD

Blood (2019) 134 (Supplement_1): SCI-24.

https://doi.org/10.1182/blood-2019-121120

Published: 2019

Journal Articles

Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)

Jorge Cortes, MD, Mansour Alfayez, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, BSN, BA, Musa E. Yilmaz, MD, Nicholas J. Short, MD, Koji Sasaki, MD, Lucia Masarova, MD, Naveen Pemmaraju, MD, Gautam M. Borthakur, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc, Naval G. Daver, MD

Blood (2019) 134 (Supplement_1): 1447.

https://doi.org/10.1182/blood-2019-127257

Published: 2019

Journal Articles

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

Christopher E. Wee, MD, Jilan Kubusek, PharmD, Irbaz Riaz, MDMMSc, Robert Wolf, PharmD, RPh, Julian R Molina, MD PhD, Naseema Gangat, MBBS

Blood (2019) 134 (Supplement_1): 2138.

https://doi.org/10.1182/blood-2019-127367

Published: 2019

Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Blood (2019) 134 (Supplement_1): 2015.

https://doi.org/10.1182/blood-2019-126238

Published: 2019

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype

Bachar Samra, MD, Guillaume Richard-Carpentier, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Veronica A Guerra, MD, Naval G. Daver, MD, Courtney D. DiNardo, MDMSc, Ghayas C. Issa, MD, Prithviraj Bose, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD

Blood (2019) 134 (Supplement_1): 3834.

https://doi.org/10.1182/blood-2019-125330

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The journey of a thousand miles begins with 1 step

Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders

Association between Inflammatory Markers and Abnormal Neurological, Neurocognitive and Magnetic Resonance Imaging (MRI) Findings in Children with Sickle Cell Anemia in Uganda

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Faster Diagnosis of TTP Using New Technoscreen Adamts-13 Activity Assay

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

MRI Evaluation of Liver and Cardiac Iron Overload Impact on Hematopoietic Stem Cell Transplantation with β-Thalassemia Major

Sensing and Sensibility: Programming Smarter Chimeric Antigen Receptor T Cells

Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only